Jul 19, 2024, 13:45
Homologous recombination deficient breast cancer are more sensitive to chemo-radiotherapy
Memorial Sloan Kettering Radiation Oncology shared on X about a recent paper titled “Increased synthetic cytotoxicity of combinatorial chemo-radiotherapy in homologous recombination deficient tumors” in International Journal of Radiation Oncology, Biology, Physics.
Authors. Jennifer Ma, Rachna Shah, Andrew C. Bell, Jorge S. Reis-Filho, Nadeem Riaz, Simon N. Powell et al.
“New in International Journal of Radiation Oncology, Biology and Physics – The Red Journal from Dr Jennifer Ma et al: Homologous recombination deficient breast cancer (HRD via BRCA 1/2, functional test or mutational signature) are more sensitive to chemoRT vs isogenic controls or tumors without HRD mutational signature.”